Media stories about NephroGenex (NASDAQ:NRX) have been trending somewhat negative recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. NephroGenex earned a news sentiment score of -0.03 on Accern’s scale. Accern also assigned news coverage about the healthcare company an impact score of 46.9582623939917 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of NephroGenex (NASDAQ NRX) opened at 0.1401 on Friday. NephroGenex has a 12 month low of $0.10 and a 12 month high of $8.90. The firm has a 50-day moving average of $0.40 and a 200 day moving average of $1.17.

WARNING: This report was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at

NephroGenex Company Profile

NephroGenex, Inc is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe.

Receive News & Ratings for NephroGenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NephroGenex Inc and related companies with's FREE daily email newsletter.